What Is the CJC-1295 / Ipamorelin Combo?

The CJC-1295 / Ipamorelin combo is a single research preparation that pairs CJC-1295 — a growth-hormone-releasing hormone (GHRH) analog that acts on the GHRH receptor (GHRH-R) — with Ipamorelin, a selective ghrelin/growth-hormone-secretagogue (GHS-R) receptor agonist. The two are blended together because, in preclinical and laboratory research, they engage two distinct and complementary nodes of the growth-hormone (GH) axis rather than the same one.

Research-use-only (RUO) note: this article describes laboratory and animal research findings. The combination is intended for in-vitro and non-human research only. It is not a drug, is not FDA-approved, and is not for human use.

What is in the combo?

• CJC-1295 — a synthetic GHRH analog. In published research it binds the GHRH receptor and, in long-acting formulations, attaches to plasma albumin to extend its duration of activity.
• Ipamorelin — a pentapeptide described in the literature as the first selective GH secretagogue. It acts on the GHS-R1a (ghrelin) receptor, a different receptor from the one CJC-1295 targets.

Why are CJC-1295 and Ipamorelin combined?

The two peptides are paired in research preparations because they are reported to act through separate but parallel signaling pathways of the GH axis. CJC-1295 engages the GHRH-R pathway (classically associated with cAMP signaling), while Ipamorelin engages the GHS-R1a pathway (associated with phospholipase C and intracellular calcium release). Because these are distinct receptor systems, investigators have studied them together to observe how the two complementary inputs behave in the same model. For a side-by-side breakdown, see our CJC-1295 vs Ipamorelin comparison.

CJC-1295 in research

CJC-1295 has been characterized in the literature as a long-acting GHRH analog. In a randomized, placebo-controlled study in healthy adults (Teichman et al., 2006), subcutaneous administration produced dose-dependent, prolonged increases in plasma GH and IGF-I, with an estimated elimination half-life of roughly 5.8–8.1 days — a duration the authors attributed to binding to endogenous albumin. For more, see our full CJC-1295 article.

Ipamorelin in research

Ipamorelin was introduced by Raun et al. (1998) as the first selective GH secretagogue. In that work it acted through the GHS/GHRP receptor and, notably, did not raise ACTH or cortisol levels meaningfully above those seen with GHRH stimulation — even at doses far above its GH-releasing threshold — distinguishing it from earlier secretagogues such as GHRP-6. For more, see our full Ipamorelin article.

Research status and safety

This combination is supplied strictly as a research material. It is research-use-only, is not approved by the FDA for any therapeutic application, and is not intended for human or veterinary use, consumption, or clinical administration. It should be handled only by qualified personnel in an appropriate laboratory setting. No safety, efficacy, or benefit claims for humans are made or implied.

Handling

Research peptides are typically supplied as a lyophilized (freeze-dried) powder that must be reconstituted before laboratory use. See our reconstitution guide for general handling and storage practices. This guide does not include or imply any dosing for human use.

FAQ

Is the CJC-1295 / Ipamorelin combo a single product or two separate vials? On Bolt Peptide it is offered as one research preparation pairing the two peptides. Format and contents are listed on the product page.

Why pair a GHRH analog with a GHS-R agonist instead of using one alone? Because they act on different receptors (GHRH-R vs. GHS-R1a), the two are studied together so researchers can observe two complementary inputs to the GH axis within a single model. This is a research rationale only, not a statement of human effect.

Can this be used by people? No. It is a research-use-only material, is not FDA-approved, and is not for human consumption or administration.

References

1. Teichman SL, et al. Prolonged stimulation of GH and IGF-I by CJC-1295, a long-acting GHRH analog, in healthy adults. J Clin Endocrinol Metab. 2006.
2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998.

Explore more research peptides in our peptide catalog, or view the CJC-1295 / Ipamorelin combo.

For research use only. Not a drug, food, cosmetic, or supplement; not for human or veterinary use. Statements have not been evaluated by the FDA.